So. . . here is the Lilly version, for Q3 2023. And it is… right in line with everyone, except… Pfizer, as adjusted for size of entity. [That is, Pfizer’s spend is… outsized.]

This is the detail — on Lilly’s spend, through three-quarters of 2023 — and plainly, the focus here is protecting insulin pricing, indeed:

…Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil….

[Senate] Patient protection; Drug supply chain and shortages; Drug pricing, coverage, value and access; Transparency; Intellectual property; Health insurance accessibility; Implementation of the “Inflation Reduction Act” (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act….

[House] Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement, coverage and value; Implementation of the “Inflation Reduction Act” (HR.5376); CMS National Coverage Determination on Alzheimer’s disease; The INSULIN Act….

Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access….

Pharmaceutical intellectual property issues….

Implementation of the Tax Cuts and Jobs Act; Domestic manufacturing tax incentives; Expensing of research and development costs; Global minimum tax….

Hospital discounts; 340B program….

Now you are in the know — Lilly obviously focuses on preserving government payor/reimbursement levels, for its insulin products. That, and justifying the vast price increases seen over the last decade in the diabetes therapies regimens. Smile. Merck and Amazon’s health spend — yet to come, this week. Onward.

नमस्ते